Cargando…

Doxycycline in the Coronavirus Disease 2019 Therapy

Acute respiratory syndrome, associated with coronavirus 2 (SARS-CoV-2), is the most important medical and epidemic problem of today. The biggest challenge is to find an effective treatment and to reduce the need for hospitalisation. In the article, the patients with mild to moderate coronavirus dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Dorobisz, Karolina, Dorobisz, Tadeusz, Janczak, Dariusz, Zatoński, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464303/
https://www.ncbi.nlm.nih.gov/pubmed/34584416
http://dx.doi.org/10.2147/TCRM.S314923
_version_ 1784572601873465344
author Dorobisz, Karolina
Dorobisz, Tadeusz
Janczak, Dariusz
Zatoński, Tomasz
author_facet Dorobisz, Karolina
Dorobisz, Tadeusz
Janczak, Dariusz
Zatoński, Tomasz
author_sort Dorobisz, Karolina
collection PubMed
description Acute respiratory syndrome, associated with coronavirus 2 (SARS-CoV-2), is the most important medical and epidemic problem of today. The biggest challenge is to find an effective treatment and to reduce the need for hospitalisation. In the article, the patients with mild to moderate coronavirus disease 2019 (COVID-19) treated with doxycycline with significant improvement have been discussed. Doxycycline is a known antibiotic, but also an anti-inflammatory and immunomodulatory drug, so it seems to be ideal for the treatment of COVID-19. Doxycycline, as an easily available and low-cost medication, should be considered as a COVID-19 therapy in all patients in the first days of the symptoms of a SARS-CoV-2 infection. Due to its immunomodulatory, anti-inflammatory, cardioprotective and antiviral effects, it seems to be an ideal drug for patients with mild, moderate and severe disease. A large multicentre study is needed to evaluate the effects of this medication.
format Online
Article
Text
id pubmed-8464303
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-84643032021-09-27 Doxycycline in the Coronavirus Disease 2019 Therapy Dorobisz, Karolina Dorobisz, Tadeusz Janczak, Dariusz Zatoński, Tomasz Ther Clin Risk Manag Case Series Acute respiratory syndrome, associated with coronavirus 2 (SARS-CoV-2), is the most important medical and epidemic problem of today. The biggest challenge is to find an effective treatment and to reduce the need for hospitalisation. In the article, the patients with mild to moderate coronavirus disease 2019 (COVID-19) treated with doxycycline with significant improvement have been discussed. Doxycycline is a known antibiotic, but also an anti-inflammatory and immunomodulatory drug, so it seems to be ideal for the treatment of COVID-19. Doxycycline, as an easily available and low-cost medication, should be considered as a COVID-19 therapy in all patients in the first days of the symptoms of a SARS-CoV-2 infection. Due to its immunomodulatory, anti-inflammatory, cardioprotective and antiviral effects, it seems to be an ideal drug for patients with mild, moderate and severe disease. A large multicentre study is needed to evaluate the effects of this medication. Dove 2021-09-21 /pmc/articles/PMC8464303/ /pubmed/34584416 http://dx.doi.org/10.2147/TCRM.S314923 Text en © 2021 Dorobisz et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Series
Dorobisz, Karolina
Dorobisz, Tadeusz
Janczak, Dariusz
Zatoński, Tomasz
Doxycycline in the Coronavirus Disease 2019 Therapy
title Doxycycline in the Coronavirus Disease 2019 Therapy
title_full Doxycycline in the Coronavirus Disease 2019 Therapy
title_fullStr Doxycycline in the Coronavirus Disease 2019 Therapy
title_full_unstemmed Doxycycline in the Coronavirus Disease 2019 Therapy
title_short Doxycycline in the Coronavirus Disease 2019 Therapy
title_sort doxycycline in the coronavirus disease 2019 therapy
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464303/
https://www.ncbi.nlm.nih.gov/pubmed/34584416
http://dx.doi.org/10.2147/TCRM.S314923
work_keys_str_mv AT dorobiszkarolina doxycyclineinthecoronavirusdisease2019therapy
AT dorobisztadeusz doxycyclineinthecoronavirusdisease2019therapy
AT janczakdariusz doxycyclineinthecoronavirusdisease2019therapy
AT zatonskitomasz doxycyclineinthecoronavirusdisease2019therapy